Physician’s Profile

Julia J. Wattacheril, MD, MPH

Director of the Nonalcoholic Fatty Liver Disease Program
NewYork-Presbyterian/Weill Cornell
Board Certificates: 
Transplant Hepatology
Internal Medicine
Nonalcoholic fatty liver disease
Liver Transplantation
Liver Cancer
Chronic Liver Disease
Non-alcoholic fatty liver disease (including non-alcoholic steatohepatitis)
Transplant hepatology
Hepatocellular carcinoma
Metabolic liver diseases
Lipid metabolism
Insulin resistance

Dr. Wattacheril's clinical specialties include all aspects of transplant hepatology, general hepatology and gastroenterology with emphasis on metabolic liver disease and obesity. She specializes in nonalcoholic fatty liver disease as well as all forms of hepatitis, chronic liver disease, and liver cancer in addition to liver transplantation. Her research interests include hepatic steatosis, insulin resistance, gut hormones and metabolic liver disease in adults. Her current research concentrates on the relationship between proteins and lipids that differentiate steatosis from steatohepatitis using an integrated omics approach.

Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, Gawrieh S, DeLemos A, Scanga A, Chalasani N, Wattacheril J. "Gender Matters: Characteristics of Hepatocellular Carcinoma in Women from a Large, Multicenter Study in the United States." Accepted for publication in American Journal of Gastroenterology.
Wattacheril J. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.Gastroenterol Clin North Am. 2020 Mar;49(1):141-149. PMID: 32033760 Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther. 2019; 50(7):809-821. PMID: 31475372
Wattacheril J, Issa D, Sanyal A. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. Annu Rev Pharmacol Toxicol. 2017 Oct 20. doi: 10.1146/annurev-pharmtox-010617-052545.
Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YI, Goodarzi MO, Taylor KD, Yates KP, Tonascia J, Rotter JI. Genome Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. J Pediatr. 2017 Sep 14. 
Issa D, Wattacheril J, Sanyal AJ. Treatment options for nonalcoholic steatohepatitis – a safety evaluation. Expert Opin Drug Saf.  2017 Jul 6:1-11. doi:10.1080/14740338.2017.1343299.
Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J. Risk factors for hepato­cellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol 2017; 9(7): 385-390
Wattacheril, J, Rose, K. L., Hill, S., Lanciault, C., Murray, C. R., Washington, K., Williams, B., English, W., Spann, M., Clements, R., Abumrad, N., and Flynn, C. R. (2017) NAFLD Phosphoproteomics: A Functional Piece of the Precision Puzzle. Hepatol Res, doi: 10.1111/hepr.12885.
Wattacheril J, Sanyal AJ. Lean NAFLD: An Underrecognized Outlier. Curt Hepatol Rep. 2016 Jun;15(2):134-139, Epub 2016 Apr 14. PMID: 27668144
Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016 Feb 13.
Wattacheril, Julia and Joseph Awad. “Acute Management of Portal Hypertensive Bleeding” Jarnagin & Blumgart: Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas 5/e, 2012, 2016
Garcia A, Kasim N, Gonzalez, R, Antoun J, Eckert E, Marks P, Wattacheril J, Abumrad N, Tamboli R, Walle T, Dunn J, Flynn CR. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS One. 2015 Nov 23;10(11):e0142676. dos: 10.1371/journal.pone.0142676
Sharifnia T, Antoun J, Suarez G, Wattacheril J, Wilson K, Peek RM, Abumrad N, and Flynn CF. Hepatic TLR4 Signaling in Obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8. doi: 10.1152/ajpgi.00304.2014
Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, et al. (2013) Differential Intrahepatic Phospholipid Zonation in Simple Steatosis and Nonalcoholic Steatohepatitis. PLoS ONE 8(2): e57165. doi:10.1371/journal.pone.0057165
Wattacheril, J. and Chalasani, N. (2012), Nonalcoholic fatty liver disease (NAFLD): Is it really a serious condition?. Hepatology, 56: 1580–1584. doi: 10.1002/hep.26031
Wattacheril, J. and Chalasani, N. (2012), Management of nonalcoholic fatty liver disease: Role of bariatric surgery. Clinical Liver Disease, 1: 118–120. doi: 10.1002/cld.80
Wattacheril, J and Brown, RS. “Living Donor Transplantation for Adult Acute Liver Failure”, Controversies in Hepatology: The Experts Analyze Both Sides. Editor: Donald Jensen. Thorofare, New Jersey, Slack Inc, 2011. ISBN: 13 978-1-55642-950-7
Hajri, Tahar, Huan Tao, Julia Wattacheril, Pamela Marks-Shulman and Naji Abumrad. Regulation of adiponectin production by insulin: Interactions with tumor necrosis factor-α and interleukin 6. Am J Physiol Endocrinol Metab 2011 Feb 300(2): E350–E360. PMID: 21062957.
Abumrad NN, Breitman I, Wattacheril J, Hubbard WJ, Chaudry IH. “Metabolic and Inflammatory Responses in Trauma and Infection”, Mastery of Surgery sixth edition, Joseph E. Fischer (editor), 2011, pp. 1-25
Saliba J, Wattacheril J, Abumrad NN (2009) Endocrine and metabolic response to gastric bypass. Curr Opin Clin Nutr Metab Care, 12:515-21. Review. PMID: 19535977
Wattacheril J, Kramer JR, Richardson P, Havemann BD, Green LK, Le A, El-Serag HB (2008). Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther, 28:1166-74. PMID: 18691351.